Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 143
SponsorCentre Hospitalier Universitaire de Nice
About this trial
Background. Bacillus cereus group (Bc) comprises twenty-six closely related species of spore-forming environmental bacteria. Recently, increased sepsis and septic shock caused by Bc were reported in preterm neonates (PN), and the mortality rate can reach up to 30%. Using Whole Genome Sequencing (WGS) increasingly used to characterize Bc strains, The team aimed to determine an accurate identification to the species level of the strains involved in Bc invasive infections in preterm neonates in France and study their virulome profile.Methods. The team performed WGS for 40 neonate clinical strains responsible for invasive infections in PN. A screening of virulence genes was performed to characterize strains associated with poor prognosis. Clinical data were collected and all clinical and genomic findings were analyzed for risk factors for death.
"
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Premature newborn (i.e born before 37 last menstrual periods) with invasive infection caused by B. cereus (strains isolated from blood culture and cerebrsopinal fluid)
Disqualifiers
None
Trial population
The premature newborn included in the study were recruited from 14 NICU in 14 Tertiary Care center in France. This study is a national retrospective study
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Premature neonates with invasive infection caused by Bacillus cereus
Biological/VaccineThe whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Mortality
The mortality at D28 after birth was collected in patients record.
Time frame
28 days after birthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov